sublingual vs injectable tirzepatide Quick Update Comparing Oral and Injectable Forms

Inhibition of SGLT2 emerges as a potential approach for NAFLD/NASH treatment both by reduction of hyperglycemia and body weight and, possibly, through reduction of oxidative stress and inflammation

Inhibiting RB protein in vivo promotes the efficacy of sorafenib, and RB protein can be used as an indicator of sorafenib sensitivity (Louandre et al., 2015)

By providing a 3-month supply of medication and all necessary supplies up front, patients stay fully equipped, avoid treatment gaps, and remain psychologically engaged in their journey leading to better outcomes and long-term success

Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group